Humanigen

Business model

Clinical-stage biopharmaceutical developing immunotherapy candidates, including a COVID-19 treatment.

In brief

Developed lenzilumab, an immunotherapy candidate that saw a surge of attention during COVID-19 for potential use in treating cytokine storm, a severe immune overreaction seen in critically ill patients. After the drug failed to gain the regulatory authorization needed to reach co…

See the What Happened tab for the full account.